The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

被引:0
|
作者
Liu, Tao [1 ]
Zhou, Ping [2 ]
Jiang, Xin [3 ]
Wang, Na [1 ]
Shou, Jialing [1 ]
Fang, Yuqiang [1 ,4 ]
机构
[1] Army Med Univ, Chongqing Inst Cardiol, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China
[2] First Peoples Hosp Chongqing Liang Jiang New Area, Dept Cardiol, Chongqing 401121, Peoples R China
[3] Peoples Hosp Chongqing Da Du Kou Area, Dept Cardiol, Chongqing, Peoples R China
[4] Army Med Univ, Dept Cardiol, Chongqing Inst Cardiol, Daping Hosp, 10 Changjiang Branch Rd, Chongqing 400042, Peoples R China
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2023年 / 28卷 / 01期
基金
中国国家自然科学基金;
关键词
Angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; dilated cardiomyopathy; PREDICTORS; THERAPY; PREVALENCE; RECOVERY; INSIGHTS;
D O I
10.4103/jrms.jrms_626_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD)<= 50 mm for females or <= 55 mm for males and left ventricular ejection fraction (LVEF) >= 45%; the criteria of "partial reversal" was the decreased rate of LVEDD (Delta LVEDD) >10% or the increase rate of LVEF (Delta LVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and Delta LVEDD <10%, and LVEF <45% and Delta LVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Risk of Atrial Fibrillation Before Coronary Artery Bypass Grafting
    Johnston, Kiersten
    Stephens, Sarah
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (09) : 1239 - 1244
  • [42] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
    Alonso Hernandez, Angel
    Moreso, Francesc
    Bayes, Beatriz
    Lauzurica, Ricardo
    Sanz-Guajardo, Damaso
    Gomez-Huertas, Ernesto
    Pereira, Porfirio
    Paul, Javier
    Crespo, Josep
    Amenabar, Juan J.
    Oliver, Juan
    Seron, Daniel
    CLINICAL KIDNEY JOURNAL, 2010, 3 : II21 - II25
  • [43] Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults
    T. Dorosch
    C. A. Ganzer
    M. Lin
    A. Seifan
    Current Pain and Headache Reports, 2019, 23
  • [44] Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients
    Kido, Ryo
    Akizawa, Tadao
    Fukagawa, Masafumi
    Onishi, Yoshihiro
    Yamaguchi, Takuhiro
    Fukuhara, Shunichi
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (06) : 439 - 447
  • [45] Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers
    Diav-Citrin, Orna
    Shechtman, Svetlana
    Halberstadt, Yehudit
    Finkel-Pekarsky, Victoriya
    Wajnberg, Rebecka
    Arnon, Judy
    Di Gianantonio, Elena
    Clementi, Maurizio
    Ornoy, Asher
    REPRODUCTIVE TOXICOLOGY, 2011, 31 (04) : 540 - 545
  • [47] Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
    Douillard, Marie
    Deheb, Zineb
    Bozon, Agathe
    Raison-Peyron, Nadia
    Dereure, Olivier
    Moulis, Lionel
    Soria, Angele
    Du-Thanh, Aurelie
    WORLD ALLERGY ORGANIZATION JOURNAL, 2023, 16 (08):
  • [48] Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study
    Blackburn, DF
    Dobson, RT
    Blackburn, JL
    Wilson, TW
    Stang, MR
    Semchuk, WM
    CANADIAN JOURNAL OF CARDIOLOGY, 2005, 21 (06) : 485 - 488
  • [49] Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
    Roberto Robles, Nicolas
    Romero, Baldomero
    Fernandez-Carbonero, Enrique
    Sanchez-Casado, Emilio
    Jose Cubero, Juan
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2009, 10 (04) : 195 - 200
  • [50] Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?
    NM Kaplan
    Journal of Human Hypertension, 2000, 14 : S87 - S90